Celgene: Apremilast For Psoriatic Arthritis successfully reduced psoriatic arthritis symptoms by at least 20% versus placebo.

New Drug Approvals

Celgene data from its ongoing Phase III trial of apremilast this month showing the drug successfully reduced psoriatic arthritis symptoms by at least 20% versus placebo.

The data is good news for the 1 million diagnosed patients in the U.S. and Europe and for shareholders eager to see apremilast win market share in the multibillion dollar immunology market.

read all at

 

http://seekingalpha.com/article/1433601-celgene-apremilast-for-psoriatic-arthritis-offers-upside?source=google_news

View original post

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s